Berlin, Germany

Elisa Kieback

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Elisa Kieback: Innovator in Chimeric Antigen Receptor Technology

Introduction

Elisa Kieback is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of immunology, particularly in the development of chimeric antigen receptors (CAR) and CAR-T cell therapies. With a total of 3 patents, her work focuses on innovative solutions for treating diseases associated with pathogenic B cells.

Latest Patents

Kieback's latest patents include groundbreaking inventions related to chimeric antigen receptors and CAR-T cells that specifically bind to B Cell Maturation Antigen (BCMA). One of her notable inventions describes an isolated chimeric antigen receptor polypeptide that comprises an extracellular antigen-binding domain. This domain includes an antibody or antibody fragment that binds to BCMA, particularly targeting an epitope consisting of amino acids from residues 13 to 32 of the N-terminus of human BCMA. Additionally, her patents disclose a nucleic acid molecule encoding the CAR, genetically modified immune cells expressing the CAR, and their application in treating medical disorders linked to pathogenic B cells, such as multiple myeloma and non-Hodgkin's lymphoma.

Career Highlights

Elisa Kieback has worked at prestigious institutions, including the Max Delbrück Center for Molecular Medicine in Berlin-Buch and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association. Her research has significantly advanced the understanding and treatment of various B cell-related diseases.

Collaborations

Throughout her career, Kieback has collaborated with esteemed colleagues, including Wolfgang Uckert and Armin Rehm. These partnerships have further enriched her research and contributed to her innovative work in the field.

Conclusion

Elisa Kieback is a trailblazer in the development of CAR technology, with her patents paving the way for new therapeutic approaches to combat diseases associated with B cells. Her contributions continue to influence the field of immunology and offer hope for patients suffering from complex medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…